Skip to main content
Equibles

RHUMBLINE ADVISERS

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 1115418 BOSTON, MA
Back to RXRX Full portfolio

Position in RXRX

as of Jun 30, 2026 · filed Aug 12, 2026
Position Value
$2,389,955
+$536,415 QoQ
Shares Held
651,214
+7.9% QoQ
Ownership
0.122%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#48
of 344 holders
Holding Since
Jun 2021
21 quarters on record
Voting authority Sole 18% Shared 0% None 82%

Common Shares in RXRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. RXRX ranks #91 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 396,380 $196,893,837
2 REGN
Regeneron Pharmaceuticals, Inc.
 157,794 $98,390,870
3 MRNA
Moderna, Inc.
 809,853 $56,714,005
4 ALNY
Alnylam Pharmaceuticals, Inc.
 165,579 $49,844,246
5 INCY
Incyte Corp
 428,533 $48,578,500
6 RVMD
Revolution Medicines, Inc.
 226,008 $42,326,778
7 ROIV
Roivant Sciences Ltd.
 1,178,789 $41,717,342
8 JAZZ
Jazz Pharmaceuticals plc
 163,018 $39,282,447

All Filings in RXRX

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,389,955 651,214
2026-03-31 $1,853,540 603,759
2025-12-31 $2,074,562 507,228
2025-09-30 $2,541,430 520,785
2025-06-30 $2,617,310 517,255
2025-03-31 $1,900,035 359,175
2024-12-31 $2,258,056 334,032
2024-09-30 $2,045,984 310,468
2024-06-30 $2,110,110 281,348
2024-03-31 $2,260,916 226,772
2023-12-31 $2,160,000 219,067
2023-09-30 $1,692,187 221,201
2023-06-30 $1,927,073 257,975
2023-03-31 $1,399,886 209,878
2022-12-31 $1,585,075 205,587
2022-09-30 $2,178,263 204,724
2022-06-30 $1,535,741 188,666
2022-03-31 $887,066 123,892
2021-12-31 $2,039,737 119,074
2021-09-30 $581,784 25,284
2021-06-30 $759,857 20,818